NOUSCOM
Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy. The NousCom team is lead by experienced enterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.
NOUSCOM
Social Links:
Industry:
Biotechnology Genetics Health Care Therapeutics
Founded:
2015-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.nouscom.com
Total Employee:
11+
Status:
Active
Contact:
+41612011831
Email Addresses:
[email protected]
Total Funding:
54 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Analytics Google Tag Manager WordPress Google Universal Analytics Font Awesome Global Site Tag Mobile Non Scaleable Content
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
LSP BioVentures
LSP BioVentures investment in Series B - Nouscom
5AM Ventures
5AM Ventures investment in Series B - Nouscom
Versant Ventures
Versant Ventures investment in Series B - Nouscom
Abingworth
Abingworth investment in Series B - Nouscom
Life Sciences Partners
Life Sciences Partners investment in Series A - Nouscom
Versant Ventures
Versant Ventures investment in Series A - Nouscom
Key Employee Changes
Official Site Inspections
http://www.nouscom.com
- Host name: 77.209.214.35.bc.googleusercontent.com
- IP address: 35.214.209.77
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Nouscom"
Nouscom • History & Team
Nouscom’s leadership and research team are successful entrepreneurs, who have previously developed innovative candidate vaccines for a range of infectious diseases that include: Malaria (Ewer et al, 2013), Ebola (Stanley et al, 2014; …See details»
Nouscom - Crunchbase Company Profile & Funding
Nouscom is a developer of an immunotherapy platform that aims to create modified viral vector vaccines for cancer treatment. The company's platform …See details»
Nouscom - LinkedIn
Nouscom | 14,645 followers on LinkedIn. Nouscom is a private clinical stage immuno-oncology company developing off-the-shelf and personalized cancer immunotherapies using proprietary viral vectors ...See details»
Nouscom AG - Swiss Biotech
Nouscom is a privately held oncology company developing next-generation immunotherapies. Nouscom’s proprietary technology platform harnesses the full power of the immune response …See details»
Nouscom 2025 Company Profile: Valuation, Funding
Nouscom General Information Description. Developer of an immunotherapy platform designed to develop engineered viral vector vaccines for the treatment of cancer. The company's platform utilizes a portfolio of engineered viral vectors …See details»
Nouscom Company Profile - Office Locations, Competitors ... - Craft
Nouscom develops a technology platform that is based on tumor targeted oncolytic viruses and patient-specific cancer vaccines. The Company offers Endovax antigenless vaccine that …See details»
Nouscom - Leadership Team - The Org
The Leadership Team at Nouscom is responsible for guiding the strategic direction and overall vision of the company, ensuring effective development and commercialization of innovative …See details»
Nouscom - The Org
Nouscom are a biotech company working to develop a series of new, potent immunotherapeutics capable of selectively killing tumor cells. Industries Biotechnology , Health Care + 2See details»
Nouscom - Contacts, Employees, Board Members, Advisors
Organization. Nouscom . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 9. Number of Board …See details»
NOUSCOM AG Company Profile | Basel, BASEL-STADT, Switzerland ...
Find company research, competitor information, contact details & financial data for NOUSCOM AG of Basel, BASEL-STADT. Get the latest business insights from Dun & Bradstreet.See details»
Nouscom - Overview, News & Similar companies | ZoomInfo.com
Who is Nouscom. Nouscom is a privately held oncology company developing next-generation immunotherapies. Nouscom's proprietary technology platform harnesses the fu ll power of the …See details»
Nouscom - EQT Group
Do You Want to Know More? We are eager to explore how we can achieve great things together.See details»
Nouscom Company Information - Funding, Investors, and More
Nouscom, based in Basel, has strong potential in the biotech space with its innovative viral vector-based vaccines for cancer treatment. This technology sets it apart from traditional methods …See details»
Nouscom Raises €67.5 million ($72 million) in Oversubscribed …
14th November 2023 – New specialist European and US life sciences investors join existing investors to enable Nouscom to continue advancing the clinical development of its portfolio of …See details»
Nouscom | Biotechnology - The Pharmaletter
May 29, 2018 Nouscom is a privately-held immunotherapy company developing genetic neoantigen vaccines and oncolytic viruses for the prevention and treatment of cancer. The …See details»
Nouscom - Funding, Financials, Valuation & Investors - Crunchbase
Nouscom is a biotech company that develops a series of immunotherapies that are capable of selectively killing tumor cells. New. Resources. Advanced Search. ... How much funding has …See details»
Nouscom Raises €67.5 million ($72 million) in - GlobeNewswire
Nov 14, 2023 Nouscom Rick Davis, COO E : [email protected] T : +41 61 201 1835: MEDiSTRAVA Consulting Sylvie Berrebi, Mark Swallow E : [email protected] T : …See details»
Nouscom Presents Positive Final Results from Completed Phase
20 hours ago Nouscom’s lead program, NOUS-209, is an off-the-shelf immunotherapy in advanced clinical development for cancer interception in LS and the treatment of MSI-mCRC. …See details»
Nouscom • Cancer Genetic Vaccines and Armored Oncolytic Viruses
In March 2021, Nouscom received regulatory approval to initiate a multicenter Phase 1b trial of NOUS-PEV and will be enrolling patients in Spain and other European countries. The trial will …See details»
AACR 2025: Nouscom reports early but promising response in …
1 day ago Off-the-shelf cancer vaccine specialist Nouscom AG announced positive final results for its lead product, Nous-209, showing there was a “highly potent” and durable immune …See details»